Page last updated: 2024-11-11

2,6-nonadienal, (e,z)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-nonadienal: RN given for (trans,trans)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6428555
CHEMBL ID3185994
CHEBI ID89743
SCHEMBL ID17627772
MeSH IDM0327111

Synonyms (15)

Synonym
2,4-nonadienal
(z, e)-2,4-nonadien-1-al
(2z,4e)-nona-2,4-dienal
tox21_301826
cas-557-48-2
NCGC00255406-01
dtxcid9027104
ZHHYXNZJDGDGPJ-MDAAKZFYSA-N
CHEMBL3185994
chebi:89743 ,
2,4-nonadien-1-al
SCHEMBL17627772
(z,e)-2,4-nonadienal
fema 3212
Q27161933
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polyunsaturated fatty aldehydeAny fatty aldehyde containing more than one double or triple bond located at any position in the aliphatic chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency61.64480.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency61.64480.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency54.48270.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency38.44340.000221.22318,912.5098AID1259243; AID743035; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency48.96620.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.37620.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency48.96620.000817.505159.3239AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency24.33650.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency51.95360.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency54.94100.001019.414170.9645AID743191
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency67.29850.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency61.64480.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency46.72960.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's1 (9.09)29.6817
2010's5 (45.45)24.3611
2020's4 (36.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.61 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]